Cellular cardiomyoplasty in refractory angina: experimental substantiation of the optimal method and clinical experience
Open Access
- 12 June 2025
- journal article
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 92 (3) , 34-44
Abstract
Objective. Experimental substantiation of the optimal method of cellular cardiomyoplasty and familiarization with clinical experience. Materials and methods. The study included experimental and clinical parts. The experimental part was performed on 122 rats of the Wistar–Cayote inbred line weighing 200 – 220 g, which were induced with myocardial infarction by stitching and ligation of the anterior interventricular artery. The animals were divided into five groups, and each group (except for the control) was treated with different routes of stem cell injection. Markers of neoangiogenesis in the blood serum, concentration of vascular endothelial growth factor, endothelin–1 level were studied in the dynamics, echocardiography was performed to calculate cardiac function. The clinical part of the study was based on the analysis of the results of treatment of 30 patients who were studied for the effectiveness of the use of autologous mesenchymal stem cells on myocardial remodeling. The diagnosis was made based on the clinical picture, anamnesis, and the results of invasive and non–invasive examination methods. Results. Experimental studies have shown a positive effect of intramyocardial injection of autologous mesenchymal stem cells on the functional reserve and metabolism of cardiomyocytes due to the paracrine effect and stimulation of angiogenesis. This was confirmed by a statistically significant increase in the level of vascular endothelial growth factor, an increase in the concentration of nitric oxide derivatives with a simultaneous decrease in the concentration of endothelin–1 to normal values. Transplantation of autologous bone marrow stem cells increased left ventricular ejection fraction (t = 2.5, p < 0.05) and stroke volume (t = 1.9, p < 0.05). Conclusions. Optimal transmyocardial injection of stem cells. The clinical study showed an improvement in total unipolar voltage from (7.3± 1.1) to (8.9± 1.8) mV after 6 months and (8.1± 1.3) mV after 12 months (p= 0.03), positive changes in intracardiac hemodynamics and reduction in the depth and area of myocardial perfusion defects, promotion of neoangiogenesis, and improvement of patients' quality of life.Keywords
This publication has 8 references indexed in Scilit:
- The Use of Left Ventricular Assist Devices in End-Stage Heart FailureCritical Care Nursing Quarterly, 2018
- Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of 123I-metaiodobenzylguanidine scintigraphyHeart and Vessels, 2018
- Hospitalisation in Patients With Heart Failure With Preserved Ejection FractionClinical Medicine Insights: Cardiology, 2018
- Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysisHeart, 2017
- Cellular mechanisms underlying cardiac engraftment of stem cellsExpert Opinion on Biological Therapy, 2017
- In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytesNature, 2012
- Cardiac Cell Therapy — Mixed Results from Mixed CellsNew England Journal of Medicine, 2006
- Cardiac Stem Cells Possess Growth Factor-Receptor Systems That After Activation Regenerate the Infarcted Myocardium, Improving Ventricular Function and Long-Term SurvivalCirculation Research, 2005